Get the Stockscreener App
6.43
0.47%
-0.02
Mind Medicine Inc stock is traded at $6.43, with a volume of 281.72K.
It is down -0.47% in the last 24 hours and down -25.78% over the past month.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
See More
Previous Close:
$6.45
Open:
$6.45
24h Volume:
281.72K
Relative Volume:
0.15
Market Cap:
$476.34M
Revenue:
$11.40B
Net Income/Loss:
$-95.73M
P/E Ratio:
-2.6245
EPS:
-2.45
Net Cash Flow:
$-64.37M
1W Performance:
-2.87%
1M Performance:
-25.78%
6M Performance:
-0.47%
1Y Performance:
-25.35%
1-Day Range:
$6.31
$6.5021
1-Week Range:
$5.96
$6.91
52-Week Range:
$5.0329
$12.22
Mind Medicine Inc Stock (MNMD) Company Profile
Name
Mind Medicine Inc
Sector
Industry
Phone
212-220-6633
Address
ONE WORLD TRADE CENTER, NEW YORK
Compare MNMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNMD
Mind Medicine Inc
|
6.4214 | 476.34M | 11.40B | -95.73M | -64.37M | -2.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
498.54 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
678.12 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
577.05 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.79 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.47 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Mind Medicine Inc Stock (MNMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Evercore ISI | Outperform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Jul-24-24 | Initiated | ROTH MKM | Buy |
| May-29-24 | Initiated | Robert W. Baird | Outperform |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | Canaccord Genuity | Buy |
| Dec-09-22 | Resumed | ROTH Capital | Buy |
| Nov-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-26-22 | Initiated | Oppenheimer | Outperform |
| Aug-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-04-22 | Initiated | ROTH Capital | Buy |
| Jun-28-21 | Initiated | Maxim Group | Buy |
View All
Mind Medicine Inc Stock (MNMD) Latest News
MindMed’s SWOT analysis: psychedelic stock’s journey through mental health market - Investing.com
MindMed at Leerink’s Global Healthcare Conference: Strategic Insights on Psychedelics - Investing.com India
What is HC Wainwright’s Estimate for MNMD FY2029 Earnings? - Defense World
Robert W. Baird Cuts Mind Medicine (MindMed) (NASDAQ:MNMD) Price Target to $16.00 - Defense World
Mind Medicine (MindMed)’s (MNMD) Buy Rating Reiterated at HC Wainwright - Defense World
Mind Medicine’s (MNMD) Recent Achievements Boosting Stock - Markets Insider
Rhumbline Advisers Buys 4,868 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Defense World
Oppenheimer & Co. Inc. Grows Stock Holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Defense World
Sanctuary Advisors LLC Lowers Stock Position in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Defense World
H.C. Wainwright maintains MindMed stock Buy rating, $55 target - Investing.com India
Mind Medicine’s Promising Future: Buy Rating Backed by Strong Phase 3 Prospects and Financial Position - TipRanks
Mind Medicine Inc (MNMD) Q4 2024 Earnings Call Highlights: Strat - GuruFocus.com
Mind Medicine Inc (MNMD) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance
MindMed Advances Clinical Trials and Strengthens Financial Position - TipRanks
Mind Medicine Getting An 'RFK Bump'? Retail Gets More Bullish As Stock Heads For Best Day In Over 10 Months - MSN
MindMed posts strong cash position, progress on LSD treatment - Green Market Report
Earnings call transcript: MindMed misses Q4 2024 EPS forecast, stock slides - Investing.com
Mind Medicine (MindMed) Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Mind Medicine (MindMed) Inc. SEC 10-K Report - TradingView
Mind Medicine reports Q4 EPS (41c), consensus (28c) - TipRanks
MIND MEDICINE Earnings Results: $MNMD Reports Quarterly Earnings - Nasdaq
Mind Medicine (MindMed) Inc. Loss At -$34.74 Mln In Q4 - Nasdaq
MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates - Joplin Globe
Can MindMed's $273M War Chest Transform Anxiety Treatment? Phase 3 Trials Signal Major Momentum - StockTitan
MindMed to Present at Leerink’s Global Healthcare Conference 2025 - TipRanks
Can MindMed's Conference Appearance Signal New Brain Health Breakthroughs? - StockTitan
Learn to Evaluate (MNMD) using the Charts - Stock Traders Daily
Mind Medicine (MindMed) Inc. (MNMD): Among the Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
12 Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
Mind Medicine (MindMed) (MNMD) Projected to Post Earnings on Thursday - MarketBeat
Mind Medicine (MindMed) (MNMD) Expected to Announce Quarterly Earnings on Thursday - Defense World
Mind Medicine (MindMed) (NASDAQ:MNMD) Trading Down 5.3%Here's Why - MarketBeat
When the Price of (MNMD) Talks, People Listen - Stock Traders Daily
Can MindMed's 2024 Financial Results Reveal Its Brain Health Pipeline Progress? - StockTitan
Mind Medicine (MindMed) (NASDAQ:MNMD) Stock Price Down 5.3%Time to Sell? - MarketBeat
Mind Medicine (MindMed) (MNMD) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Gap UpHere's What Happened - MarketBeat
Why Mind Medicine Stock Is Skyrocketing Today - MSN
OPNTMindMed Strengthens Board with Appointment of Two New Independent Directors - br.ADVFN.com
Mind Medicine (MNMD) Stock Surges on RFK Jr.'s HHS Confirmation - GuruFocus.com
Mind Medicine (MindMed) (NASDAQ:MNMD) Trading Down 9%Time to Sell? - MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Shares Purchased by SG Americas Securities LLC - Defense World
Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Up 5.5%Still a Buy? - MarketBeat
Mind Medicine (MindMed) (NASDAQ:MNMD) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Mind Medicine (MindMed) (NASDAQ:MNMD) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Mind Medicine Inc Stock (MNMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mind Medicine Inc Stock (MNMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Liao Carrie | Chief Accounting Officer |
Dec 26 '24 |
Sale |
7.43 |
2,273 |
16,888 |
97,270 |
| Karlin Dan | Chief Medical Officer |
Dec 26 '24 |
Sale |
7.43 |
6,643 |
49,357 |
338,013 |
| Sullivan Mark | Chief Legal Officer |
Dec 26 '24 |
Sale |
7.43 |
4,519 |
33,576 |
173,197 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):